Noxopharm Ltd. stock analysis
Want to see AU:NOX full AI Analyst Report?
Noxopharm Ltd. (NOX) Share Price & Analysis
NOX Stock Chart & Stats
- Day’s Range
- AUD 0.04 - AUD 0.04
- 52-Week Range
- AUD 0.03 - AUD 0.11
- Previous Close
- AUD 0.04
- Volume
- N/A
- Average Volume (3M)
- 200.81K
- Market Cap
- AUD 12.36M
- Enterprise Value
- AUD 30.46M
- Total Cash (Recent Filing)
- AUD 293.57K
- Total Debt (Recent Filing)
- AUD 4.57M
- Price to Earnings (P/E)
- ―
- Beta
- 1.22
- Next Earnings
- Mar 02, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Specialized Oncology Pipeline
A focused oncology and immuno-oncology strategy gives Noxopharm a clearly defined therapeutic area and the potential to build value around specialized drug candidates. Progressing assets through preclinical and clinical development, including combination approaches, supports a coherent long-term R&D platform.
Narrower Operating Losses
The material reduction in operating losses suggests improved cost control or lower expense intensity, which could moderate the rate of resource consumption. Although profitability remains distant, maintaining this improvement would strengthen operating discipline and extend the company’s ability to advance its development programs.
Improved Cash-burn Trend
A substantially smaller operating cash outflow is a constructive change in the company’s funding profile, even though cash generation remains negative. If sustained, lower burn would lengthen available financial capacity and allow more capital to remain focused on advancing oncology research and development.
Bears Say
Negative Equity And Rising Debt
Negative stockholders’ equity indicates that accumulated losses or capital structure strain have materially weakened the balance sheet. Rising debt further reduces financial flexibility, increases pressure to secure funding, and makes it harder to sustain development spending without additional capital support.
Persistent Losses And Revenue Contraction
Continued operating and net losses show that the business has not yet reached a self-sustaining earnings model. The sharp revenue contraction also limits operating leverage, making it harder for fixed development activities to be supported by internal revenue over the next several quarters.
Ongoing Dependence On External Financing
Persistent operating and free-cash-flow outflows mean Noxopharm cannot currently fund its activities from internally generated cash. Continued reliance on external financing exposes the development program to funding availability and can constrain strategic flexibility if capital becomes harder to obtain.
Noxopharm Ltd. News
NOX FAQ
What was Noxopharm Ltd.’s price range in the past 12 months?
What is Noxopharm Ltd.’s market cap?
When is Noxopharm Ltd.’s upcoming earnings report date?
How were Noxopharm Ltd.’s earnings last quarter?
Is Noxopharm Ltd. overvalued?
Does Noxopharm Ltd. pay dividends?
What is Noxopharm Ltd.’s EPS estimate?
How many shares outstanding does Noxopharm Ltd. have?
What happened to Noxopharm Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Noxopharm Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Noxopharm Ltd. Stock Smart Score
Company Description
Noxopharm Ltd.
Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy designed to augment the effectiveness of chemotherapy and radiotherapy in treating late-stage cancers. Beyond Veyonda, the company's robust development pipeline encompasses several key programs: The DARRT program, currently in Phase 1b/2a clinical trials, is addressing metastatic castration-resistant prostate cancer and other solid tumors. The LuPIN program explores a combined therapy of Veyonda and 177Lu-PSMA-617 for advanced prostate cancer. The IONIC program combines Veyonda with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, targeting various solid tumor types. Its Chemotherapy Enhancement Program (CEP) integrates Veyonda with carboplatin for patients suffering from refractory solid tumors in areas such as the breast, head and neck, lung, prostate, and ovaries. Furthermore, the NOXCOVID Program is conducting a dose escalation and expansion study of NOX66 for the treatment of COVID-19 infection. The company is also investigating potential treatments for pancreatic cancer and glioblastoma. Noxopharm collaborates with the Hudson Institute of Medical Research and The Australian National University on the research and development of therapeutic drugs for inflammatory disorders. Incorporated in 2015, the company's operations are based in Chatswood, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Olivier Laczka
- Employees
- 8
- Website
- www.noxopharm.com
- Address
- 60 Linksley Avenue, Glenhaven, NSW, 2156, AU
Noxopharm Ltd. (NOX) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 4 | 13 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 1 | 0 | 11 |









